G01N 2333/705
Assays involving receptors, cell surface antigens or cell surface determinants
G01N2333/705 (Assays involving receptors, cell surface antigens or cell surface determinants) appears on 5,181 US grants and 9,905 published applications in this corpus.
Search patents in G01N- Granted patents
- 5,181
- Published applications
- 9,905
- Assignees
- 3,408
- Inventors
- 17,791
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 3 | 0 |
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 3 | 0 |
| 1993 | 6 | 0 |
| 1994 | 8 | 0 |
| 1995 | 14 | 0 |
| 1996 | 19 | 0 |
| 1997 | 33 | 0 |
| 1998 | 80 | 0 |
| 1999 | 71 | 0 |
| 2000 | 50 | 0 |
| 2001 | 74 | 29 |
| 2002 | 83 | 155 |
| 2003 | 67 | 275 |
| 2004 | 58 | 236 |
| 2005 | 62 | 268 |
| 2006 | 94 | 265 |
| 2007 | 81 | 274 |
| 2008 | 124 | 260 |
| 2009 | 102 | 363 |
| 2010 | 181 | 360 |
| 2011 | 184 | 361 |
| 2012 | 168 | 338 |
| 2013 | 175 | 318 |
| 2014 | 193 | 376 |
| 2015 | 243 | 661 |
| 2016 | 261 | 645 |
| 2017 | 315 | 600 |
| 2018 | 372 | 572 |
| 2019 | 380 | 463 |
| 2020 | 351 | 517 |
| 2021 | 278 | 463 |
| 2022 | 241 | 451 |
| 2023 | 195 | 414 |
| 2024 | 205 | 434 |
| 2025 | 240 | 477 |
| 2026 | 156 | 330 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- G01N 2333/70503Immunoglobulin superfamilyIndexing code1,215
- G01N 2333/72For hormonesIndexing code994
- G01N 2333/70596Molecules with a "cd"-designation not provided for elsewhere in g01n2333/705Indexing code828
- G01N 2333/71For growth factorsIndexing code587
- G01N 2333/715For cytokinesIndexing code386
- G01N 2333/70546Integrin superfamilyIndexing code208
- G01N 2333/70578Ngf-receptor/tnf-receptor superfamilyIndexing code167
- G01N 2333/70571For neuromediatorsIndexing code159
All 15 subgroupsShow fewer
Recent patents
- Anti-ABCG2 antibodies and uses thereof6 Oct 2026US 12,753,241 B2William Robert Arathoon Living Trust Dated August 29, 2016
- Monoclonal antibody used for diagnosis and early onset of prostate cancer6 Oct 2026US 12,753,244 B2Taipei Medical University
- Monoclonal antibody drug sensitivity in multiple myeloma patients6 Oct 2026US 12,754,180 B2The Regents of the University of Colorado, a body corporate
- Means and methods for the diagnosis, classification and/or monitoring of pediatric tumors6 Oct 2026US 12,754,186 B2Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Drug-specific pharmacokinetic assay for IL-15 superagonist6 Oct 2026US 12,754,189 B2NantCell, Inc.
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Mhc class i molecules8 Oct 2026US 2026/0308228 A1Immudex ApS
- Multi-domain molecules8 Oct 2026US 2026/0308260 A1Immunocore Limited
- Compositions and methods for determining the effects of t cell engager8 Oct 2026US 2026/0309708 A1Arbele Limited
- Combination therapy of polio virus receptor inhibitors and fucose8 Oct 2026US 2026/0309713 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
Most cited
By later US patents
- Downmodulating an immune response with multivalent antibodies to PD-1309US 6,808,710 B1Dana-Farber Cancer Institute, Inc. · 2004
- Methods of activating a melanocortin-4 receptor pathway in obese subjects277US 8,476,227 B2Ethicon Endo-Surgery, Inc. · 2013
- Apparatus and methods for magnetic separation265US 5,200,084 AImmunicon Corporation · 1993
- Bispecific antibodies for selective immune regulation and for selective immune cell binding233US 5,601,819 AThe General Hospital Corporation · 1997
- Identification and engineering of antibodies with variant Fc regions and methods of using same227US 7,355,008 B2MacroGenics, Inc. · 2008